

Governor

JAMES V. McDONALD, M.D., M.P.H. Acting Commissioner **MEGAN E. BALDWIN**Acting Executive Deputy Commissioner

Medicaid Practitioner Administration Drugs Update

On December 15, 2022, the New York State Medicaid Drug Utilization Review (DUR) Board recommended changes to the Medicaid coverage criteria for practitioner administered drugs (PADs). The Commissioner of Health has approved the recommendations of the Board resulting in changes within NYRx, the New York Medicaid coverage criteria for PADs.

Effective April 27th, **2023**, nusinersen (Spinraza®) when provided via the medical benefit will have the following criteria:

• The patient must not have advanced disease (e.g., complete limb paralysis or permanent ventilator dependence).

For more detailed information on the DUR Board, please refer to: http://www.health.ny.gov/health_care/medicaid/program/dur/index.htm

PAD Clinical criteria worksheets are located here:

https://www.health.ny.gov/health_care/medicaid/program/practitioner_administered/ffs_practitioner_administer.htm

FFS Billing:

Drugs listed in the Physician Fee Schedule with a notation of BR (By Report) under the Maximum Fee column must be submitted on a paper HCFA 1500 claim form with a copy of the itemized invoice as documentation. Additional information can be found in our NYS Medicaid Physician Manual.

Questions and Additional Information:

- FFS billing and claim questions should be directed to the eMedNY Call Center at (800) 343-9000.
- FFS pharmacy and PAD coverage policy questions should be directed to the Medicaid Pharmacy Policy Unit by telephone at (518) 486-3209 or by email at NYRx@health.ny.gov.
- Additional information on the DUR Board is available on the <u>NYS Department of Health</u> (<u>DOH</u>) "Drug Utilization Review (<u>DUR</u>)" web page.

Additional information is available at the following websites:

https://www.health.nv.gov/health_care/medicaid/program/pharmacv.htm

http://newyork.fhsc.com

http://www.eMedNY.org

https://www.health.ny.gov